 Royalty Pharma invests in biopharmaceutical royalty streams and has deployed 18bn of capital into the space since 1996 - 50 of all deployed capital. Its portfolio of assets includes royalties from AbbVies Imbruvica, Vertex Cystic Fibrosis franchise and Biogens Tysabri - all of which make multi-blockbuster sales. 